Identification

Name
Candesartan cilexetil
Accession Number
DB00796  (APRD00420)
Type
Small Molecule
Groups
Approved
Description

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Structure
Thumb
Synonyms
Not Available
External IDs
TCV 116 / TCV-116
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-candesartanTablet32 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartanTablet16 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartanTablet4 mgOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartanTablet8 mgOralAccel Pharma IncNot applicableNot applicableCanada
Ach-candesartanTablet4 mgOralAccord Healthcare Limited2012-02-16Not applicableCanada
Ach-candesartanTablet16 mgOralAccord Healthcare Limited2012-02-16Not applicableCanada
Ach-candesartanTablet32 mgOralAccord Healthcare Limited2012-02-16Not applicableCanada
Ach-candesartanTablet8 mgOralAccord Healthcare Limited2012-02-16Not applicableCanada
Act CandesartanTablet8 mgOralActavis Pharma Company2011-11-30Not applicableCanada
Act CandesartanTablet4 mgOralActavis Pharma Company2011-11-30Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-candesartanTablet8 mgOralApotex Corporation2011-04-26Not applicableCanada
Apo-candesartanTablet32 mgOralApotex Corporation2013-07-16Not applicableCanada
Apo-candesartanTablet16 mgOralApotex Corporation2011-04-26Not applicableCanada
Apo-candesartanTablet4 mgOralApotex Corporation2011-04-26Not applicableCanada
CandesartanTablet16 mg/1OralMacleods Pharmaceuticals Limited2016-12-06Not applicableUs
CandesartanTablet4 mg/1OralMacleods Pharmaceuticals Limited2016-12-06Not applicableUs
CandesartanTablet32 mg/1OralMacleods Pharmaceuticals Limited2016-12-06Not applicableUs
CandesartanTablet8 mg/1OralMacleods Pharmaceuticals Limited2016-12-06Not applicableUs
Candesartan CilexetilTablet8 mg/1OralApotex Corporation2014-01-13Not applicableUs
Candesartan cilexetilTablet16 mg/1OralAmerincan Health Packaging2015-09-012017-02-09Us
International/Other Brands
Amias (Eureco (Netherlands), Takeda (United Kingdom)) / Blopress (Takeda)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Accel-candesartan/hctzCandesartan cilexetil (32 mg) + Hydrochlorothiazide (25 mg)TabletOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartan/hctzCandesartan cilexetil (32 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccel Pharma IncNot applicableNot applicableCanada
Accel-candesartan/hctzCandesartan cilexetil (16 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccel Pharma IncNot applicableNot applicableCanada
Act Candesartan/hctCandesartan cilexetil (16 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-09-24Not applicableCanada
Apo-candesartan/hctzCandesartan cilexetil (32 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2013-03-04Not applicableCanada
Apo-candesartan/hctzCandesartan cilexetil (16.0 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-09-25Not applicableCanada
Apo-candesartan/hctzCandesartan cilexetil (32 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-03-04Not applicableCanada
Atacand HctCandesartan cilexetil (16 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2003-01-21Not applicableUs00186 0162 54 nlmimage10 e912f487
Atacand HCTCandesartan cilexetil (16 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAstra Zeneca Lp2000-09-28Not applicableUs
Atacand HctCandesartan cilexetil (32 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2003-11-13Not applicableUs00186 0322 54 nlmimage10 f512fae7
Categories
UNII
R85M2X0D68
CAS number
145040-37-5
Weight
Average: 610.671
Monoisotopic: 610.253982839
Chemical Formula
C33H34N6O6
InChI Key
GHOSNRCGJFBJIB-UHFFFAOYSA-N
InChI
InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)
IUPAC Name
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylate
SMILES
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1

Pharmacology

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Structured Indications
Pharmacodynamics

Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of action

Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no effect on the bioavailability of candesartan from candesartan cilexetil.

Volume of distribution
  • 0.13 L/kg
Protein binding

Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells.

Metabolism

The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (<20%) occurs by O-deethylation via cytochrome P450 2C9 to form an inactive metabolite. Candesartan undergoes N-glucuronidation in the tetrazole ring by uridine diphosphate glucuronosyltransferase 1A3 (UGT1A3). O-glucuronidation may also occur. 75% of candesartan is excreted as unchanged drug in urine and feces.

Route of elimination

When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).

Half life

Approximately 9 hours.

Clearance
  • 0.37 mL/min/kg
Toxicity

No lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Candesartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Candesartan cilexetil.Experimental
AbirateroneThe metabolism of Candesartan cilexetil can be decreased when combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Acemetacin.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Candesartan cilexetil.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan cilexetil.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Alminoprofen.Experimental
AlprenololCandesartan cilexetil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanCandesartan cilexetil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineCandesartan cilexetil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Candesartan cilexetil.Approved
AmiodaroneThe metabolism of Candesartan cilexetil can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Candesartan cilexetil.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Candesartan cilexetil.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Candesartan cilexetil.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Candesartan cilexetil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Candesartan cilexetil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Candesartan cilexetil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Candesartan cilexetil can be increased when combined with Aprepitant.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Candesartan cilexetil.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Candesartan cilexetil.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Candesartan cilexetil.Approved
AvanafilAvanafil may increase the antihypertensive activities of Candesartan cilexetil.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Candesartan cilexetil.Experimental
BarbitalBarbital may increase the hypotensive activities of Candesartan cilexetil.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Candesartan cilexetil.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Candesartan cilexetil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benzydamine.Approved
BepridilCandesartan cilexetil may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Candesartan cilexetil.Approved
BethanidineBethanidine may increase the hypotensive activities of Candesartan cilexetil.Approved
BevoniumThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Candesartan cilexetil.Experimental
BimatoprostCandesartan cilexetil may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Candesartan cilexetil.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Candesartan cilexetil.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Candesartan cilexetil.Approved
BQ-123Candesartan cilexetil may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan cilexetil.Approved
BretyliumThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Candesartan cilexetil.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Candesartan cilexetil.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Candesartan cilexetil.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Candesartan cilexetil.Approved, Investigational
BupranololCandesartan cilexetil may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Candesartan cilexetil.Experimental
CafedrineCandesartan cilexetil may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CandesartanCandesartan cilexetil may increase the hypotensive activities of Candesartan.Experimental
CandoxatrilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Candesartan cilexetil can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Captopril.Approved
CarbamazepineThe metabolism of Candesartan cilexetil can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Candesartan cilexetil.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Candesartan cilexetil.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Celecoxib.Approved, Investigational
CeliprololCandesartan cilexetil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Candesartan cilexetil can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Candesartan cilexetil.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Candesartan cilexetil.Approved
CholecalciferolThe metabolism of Candesartan cilexetil can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Choline magnesium trisalicylate.Approved
CicletanineCandesartan cilexetil may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Candesartan cilexetil.Approved, Investigational
CiprofloxacinCandesartan cilexetil may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Candesartan cilexetil.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Candesartan cilexetil.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Candesartan cilexetil.Approved
ClonixinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Clonixin.Approved
CloranololCandesartan cilexetil may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Candesartan cilexetil.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Candesartan cilexetil.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Candesartan cilexetil.Approved, Investigational
CrisaboroleThe metabolism of Candesartan cilexetil can be decreased when combined with Crisaborole.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Candesartan cilexetil.Approved
CurcuminThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Curcumin.Investigational
CyclopenthiazideCandesartan cilexetil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineCandesartan cilexetil may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Candesartan cilexetil.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan cilexetil.Approved
DabrafenibThe serum concentration of Candesartan cilexetil can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candesartan cilexetil.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Delapril.Experimental
DelavirdineThe metabolism of Candesartan cilexetil can be decreased when combined with Delavirdine.Approved
DeserpidineCandesartan cilexetil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Candesartan cilexetil.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Candesartan cilexetil.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Candesartan cilexetil.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Diclofenamide.Approved
diethylnorspermineCandesartan cilexetil may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Candesartan cilexetil.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Candesartan cilexetil.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Dipyridamole.Approved
DorzolamideCandesartan cilexetil may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe metabolism of Candesartan cilexetil can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Candesartan cilexetil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Candesartan cilexetil.Approved, Investigational
DrospirenoneCandesartan cilexetil may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Droxicam.Approved
DuloxetineCandesartan cilexetil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with E-6201.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Candesartan cilexetil.Approved
EfavirenzThe metabolism of Candesartan cilexetil can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineCandesartan cilexetil may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Candesartan cilexetil.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
EpanololCandesartan cilexetil may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Candesartan cilexetil.Approved
EpoprostenolCandesartan cilexetil may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Candesartan cilexetil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Candesartan cilexetil can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Candesartan cilexetil.Approved
exisulindThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fenbufen.Approved
FenoldopamCandesartan cilexetil may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Feprazone.Experimental
Ferulic acidCandesartan cilexetil may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Candesartan cilexetil.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Candesartan cilexetil can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Fluconazole.Approved
FlunixinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Candesartan cilexetil can be decreased when combined with Fluorouracil.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Flurbiprofen.Approved, Investigational
FluvastatinThe metabolism of Candesartan cilexetil can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Candesartan cilexetil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Candesartan cilexetil can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Candesartan cilexetil.Approved, Vet Approved
GemfibrozilThe metabolism of Candesartan cilexetil can be decreased when combined with Gemfibrozil.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Candesartan cilexetil.Approved
GuanazodineCandesartan cilexetil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineCandesartan cilexetil may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Guanfacine.Approved, Investigational
GuanoclorCandesartan cilexetil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCandesartan cilexetil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCandesartan cilexetil may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Candesartan cilexetil.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Candesartan cilexetil.Experimental
HeparinHeparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational
HexamethoniumCandesartan cilexetil may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Candesartan cilexetil.Approved
HigenamineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Candesartan cilexetil.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Candesartan cilexetil.Approved
IndapamideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indapamide.Approved
IndenololCandesartan cilexetil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Candesartan cilexetil can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candesartan cilexetil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Candesartan cilexetil.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Candesartan cilexetil.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Candesartan cilexetil.Investigational
KetoconazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Candesartan cilexetil.Approved
LacidipineCandesartan cilexetil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Candesartan cilexetil.Approved
LeflunomideThe metabolism of Candesartan cilexetil can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Candesartan cilexetil.Approved, Investigational
LevodopaCandesartan cilexetil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Candesartan cilexetil.Approved, Investigational
LinsidomineCandesartan cilexetil may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Candesartan cilexetil.Approved
LobeglitazoneThe metabolism of Candesartan cilexetil can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineCandesartan cilexetil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Candesartan cilexetil.Approved
LovastatinThe metabolism of Candesartan cilexetil can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Candesartan cilexetil can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lumiracoxib.Approved, Investigational
MacitentanCandesartan cilexetil may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Magnesium salicylate.Approved
ManidipineCandesartan cilexetil may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Candesartan cilexetil.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Candesartan cilexetil.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Metamizole.Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Candesartan cilexetil.Approved
MethohexitalMethohexital may increase the hypotensive activities of Candesartan cilexetil.Approved
MethoserpidineCandesartan cilexetil may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Candesartan cilexetil.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candesartan cilexetil.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Candesartan cilexetil.Approved
MetipranololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Candesartan cilexetil.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Candesartan cilexetil.Approved, Investigational
MetyrosineCandesartan cilexetil may increase the hypotensive activities of Metyrosine.Approved
MibefradilCandesartan cilexetil may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Candesartan cilexetil can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Candesartan cilexetil can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Candesartan cilexetil.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Candesartan cilexetil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Candesartan cilexetil.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Candesartan cilexetil.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Candesartan cilexetil.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
MuzolimineCandesartan cilexetil may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Candesartan cilexetil.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
NafamostatThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Naftifine.Approved
NaftopidilCandesartan cilexetil may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Candesartan cilexetil.Approved
NaproxenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
NicardipineThe metabolism of Candesartan cilexetil can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Niflumic Acid.Approved
NiguldipineCandesartan cilexetil may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCandesartan cilexetil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Candesartan cilexetil.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Candesartan cilexetil.Approved
NitrendipineCandesartan cilexetil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Candesartan cilexetil.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Candesartan cilexetil.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Candesartan cilexetil.Approved
ObinutuzumabCandesartan cilexetil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Candesartan cilexetil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Oxaprozin.Approved
OxprenololCandesartan cilexetil may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Candesartan cilexetil.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Candesartan cilexetil.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Candesartan cilexetil.Approved
PenbutololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Candesartan cilexetil.Approved, Vet Approved
PentoliniumCandesartan cilexetil may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Candesartan cilexetil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
PhenobarbitalThe metabolism of Candesartan cilexetil can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineCandesartan cilexetil may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Candesartan cilexetil.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Candesartan cilexetil can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Candesartan cilexetil.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Candesartan cilexetil.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
Platelet Activating FactorCandesartan cilexetil may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideCandesartan cilexetil may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Candesartan cilexetil.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Candesartan cilexetil.Approved
PrimidoneThe metabolism of Candesartan cilexetil can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Candesartan cilexetil.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Candesartan cilexetil.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Candesartan cilexetil.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Candesartan cilexetil.Approved
PTC299The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with PTC299.Investigational
PyrimethamineThe metabolism of Candesartan cilexetil can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Candesartan cilexetil.Approved
RamiprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Candesartan cilexetil.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Candesartan cilexetil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Candesartan cilexetil.Approved
RemikirenRemikiren may increase the hypotensive activities of Candesartan cilexetil.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Candesartan cilexetil.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Investigational
RifampicinThe metabolism of Candesartan cilexetil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Candesartan cilexetil can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Candesartan cilexetil.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Candesartan cilexetil.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Riociguat.Approved
RisperidoneCandesartan cilexetil may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabCandesartan cilexetil may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Candesartan cilexetil.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Candesartan cilexetil.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Candesartan cilexetil.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Candesartan cilexetil.Approved
SafrazineSafrazine may increase the hypotensive activities of Candesartan cilexetil.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salsalate.Approved
SaprisartanCandesartan cilexetil may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe metabolism of Candesartan cilexetil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational, Vet Approved
SelexipagCandesartan cilexetil may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Candesartan cilexetil.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Candesartan cilexetil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Candesartan cilexetil.Approved
SitaxentanCandesartan cilexetil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Candesartan cilexetil.Approved
Sodium phosphateCandesartan cilexetil may increase the nephrotoxic activities of Sodium phosphate.Approved
SorafenibThe metabolism of Candesartan cilexetil can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Candesartan cilexetil.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Candesartan cilexetil.Approved
SRT501The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Candesartan cilexetil.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Candesartan cilexetil.Approved, Investigational
SulfadiazineThe metabolism of Candesartan cilexetil can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Candesartan cilexetil.Approved, Investigational
TalinololCandesartan cilexetil may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Candesartan cilexetil.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Teriflunomide.Approved
TerlipressinCandesartan cilexetil may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineCandesartan cilexetil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Candesartan cilexetil.Approved, Investigational, Withdrawn
TheodrenalineCandesartan cilexetil may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Candesartan cilexetil.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Candesartan cilexetil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Candesartan cilexetil.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tiaprofenic acid.Approved
TiboloneCandesartan cilexetil may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Candesartan cilexetil can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Candesartan cilexetil can be decreased when combined with Ticlopidine.Approved
TicrynafenCandesartan cilexetil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Candesartan cilexetil.Approved
TinoridineThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan cilexetil.Approved
TolazolineCandesartan cilexetil may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Candesartan cilexetil can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Candesartan cilexetil.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tolmetin.Approved
TolonidineCandesartan cilexetil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Candesartan cilexetil.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Candesartan cilexetil.Approved
TopiroxostatThe metabolism of Candesartan cilexetil can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Candesartan cilexetil.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Candesartan cilexetil.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan cilexetil.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Candesartan cilexetil.Approved
TravoprostTravoprost may increase the hypotensive activities of Candesartan cilexetil.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Candesartan cilexetil.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Candesartan cilexetil.Approved
TribenosideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tribenoside.Experimental
TrichlormethiazideCandesartan cilexetil may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Candesartan cilexetil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Candesartan cilexetil.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candesartan cilexetil.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Candesartan cilexetil.Approved, Investigational
UnoprostoneCandesartan cilexetil may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Candesartan cilexetil.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Candesartan cilexetil can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Candesartan cilexetil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Candesartan cilexetil.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan cilexetil.Approved
VincamineCandesartan cilexetil may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Candesartan cilexetil.Approved, Investigational
VinpocetineCandesartan cilexetil may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Candesartan cilexetil can be decreased when combined with Voriconazole.Approved, Investigational
XipamideCandesartan cilexetil may increase the hypotensive activities of Xipamide.Experimental
XylometazolineCandesartan cilexetil may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Candesartan cilexetil.Approved, Vet Approved
ZafirlukastThe metabolism of Candesartan cilexetil can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zomepirac.Withdrawn
Food Interactions
  • Administer on a regular basis, at about the same time each day.
  • Take without regard to meals.

References

Synthesis Reference

Marina Etinger, Boris Fedotev, Ben-Zion Dolitzky, "Preparation of candesartan cilexetil." U.S. Patent US20050131037, issued June 16, 2005.

US20050131037
General References
  1. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66. [PubMed:13678868]
  2. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275]
  3. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650]
  4. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660]
  5. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328]
External Links
PubChem Compound
2540
PubChem Substance
46508342
ChemSpider
2444
BindingDB
50318907
ChEBI
3348
ChEMBL
CHEMBL1014
Therapeutic Targets Database
DAP001442
IUPHAR
587
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Candesartan
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
FDA label
Download (49.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceEsophagus, Barrett1
1Active Not RecruitingOtherMethamphetamine Abuse / Methamphetamine Dependence / Substance Abuse1
1Active Not RecruitingTreatmentHealthy Male Subjects1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHypertension,Essential1
1CompletedNot AvailableRespiratory Disorders1
1CompletedBasic ScienceHypertensive1
1CompletedTreatmentChronic Kidney Disease (CKD) / Hyperphosphataemia1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHypertension,Essential1
1CompletedTreatmentHypertensive8
1Not Yet RecruitingNot AvailableHealthy Male Subjects1
1Not Yet RecruitingTreatmentHypertensive1
1Unknown StatusBasic ScienceHealthy Volunteers1
1, 2RecruitingTreatmentCardiorenal Syndrome (CRS)1
2Active Not RecruitingTreatmentDependence, Cocaine1
2CompletedPreventionCancer, Breast / Heart Failure, Unspecified1
2CompletedTreatmentAging / Cognitive Impairments / Hypertensive1
2CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
2CompletedTreatmentCluster Headache1
2CompletedTreatmentHypertension,Essential3
2CompletedTreatmentType 2 Diabetes Mellitus and Microalbuminuria1
2RecruitingTreatmentHypertension,Essential1
2RecruitingTreatmentMild Cognitive Impairment (MCI)1
2Unknown StatusNot AvailableHypertrophic Cardiomyopathy1
2Unknown StatusTreatmentHypertension,Essential1
2WithdrawnTreatmentChronic Hepatitis C Infection1
2, 3CompletedTreatmentChronic Migraine / Migraine With Aura / Migraine Without Aura1
2, 3CompletedTreatmentDiabetes1
3Active Not RecruitingPreventionHypertensive / Mild Cognitive Impairment (MCI)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionHypertensive1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentCholesterolemia / Hypertensive1
3CompletedTreatmentCongestive Heart Failure (CHF)3
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHypertensive6
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentProteinuria1
3CompletedTreatmentStrokes1
3CompletedTreatmentType 2 Diabetes Mellitus1
3RecruitingTreatmentHypertensive1
3TerminatedTreatmentHeart Failure, Unspecified1
3Unknown StatusNot AvailableHypertensive1
3Unknown StatusTreatmentAortic Valve Stenosis1
3Unknown StatusTreatmentAortic Valve Stenosis / Left Ventricular Hypertrophy / Nonvalvular Atrial Fibrillation1
3Unknown StatusTreatmentCardiovascular Disease (CVD) / Hypertensive1
3Unknown StatusTreatmentHypertension,Essential2
3WithdrawnTreatmentEssential Arterial Hypertension2
3WithdrawnTreatmentHypertensive1
4CompletedOtherBMI >30 kg/m2 / Hypertensive / Resistant Hypertension / White Coat Hypertension1
4CompletedPreventionCardiovascular Disease (CVD) / Strokes1
4CompletedPreventionCoronary Artery Disease / Hypertensive1
4CompletedScreeningChronic Kidney Disease (CKD) / Hypertensive / Proteinuria1
4CompletedTreatmentAngiotensin Converting Enzyme / Angiotensin Receptor Blockers / Cardiopulmonary Bypass / Coronary Artery Disease / Fibrinolysis / Inflammatory Reaction1
4CompletedTreatmentBMI >30 kg/m2 / Hypertensive2
4CompletedTreatmentCongestive Heart Failure (CHF) / Hypertensive1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHypertensive3
4CompletedTreatmentHypertensive / Left Ventricular Hypertrophy1
4CompletedTreatmentMitral Valve Insufficiency1
4CompletedTreatmentNon-diabetic Nephropathy With Hypertension1
4CompletedTreatmentStage II Hypertension1
4Not Yet RecruitingTreatmentHypertensive1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingTreatmentAcute Heart Failure (AHF)1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4TerminatedBasic ScienceDepression / Hypertensive1
4TerminatedTreatmentBMI >30 kg/m2 / Glucose tolerance impaired1
4Unknown StatusEducational/Counseling/TrainingType 2 Diabetes Mellitus1
4Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
4Unknown StatusTreatmentCardiovascular Disease (CVD) / Kidney Failure,Chronic1
4Unknown StatusTreatmentCerebrovascular Accidents / Stroke, Acute1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hypertensive1
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentHypertensive1
4Unknown StatusTreatmentType I Diabetes1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Heart Diseases / Hypertensive1
Not AvailableCompletedNot AvailableCohort Study / Heart Failure, Unspecified1
Not AvailableCompletedNot AvailableHypertensive3
Not AvailableCompletedPreventionDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Hypertensive1
Not AvailableTerminatedPreventionAcute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI) / Angina Pectoris / Hypertensive / Myocardial Ischemia1
Not AvailableUnknown StatusTreatmentHypertensive2

Pharmacoeconomics

Manufacturers
  • Astrazeneca pharmaceuticals lp
Packagers
Dosage forms
FormRouteStrength
TabletOral16 mg/1
TabletOral32 mg
TabletOral4 mg
TabletOral4 mg/1
TabletOral
TabletOral16 mg
TabletOral8 mg
TabletOral32 mg/1
TabletOral8 mg/1
Prices
Unit descriptionCostUnit
Atacand 30 4 mg tablet Bottle75.98USD bottle
Atacand 30 8 mg tablet Bottle74.96USD bottle
Atacand hct 32-25 mg tablet3.64USD tablet
Atacand hct 32-12.5 mg tablet3.43USD tablet
Atacand 32 mg tablet3.36USD tablet
Atacand hct 16-12.5 mg tablet3.36USD tablet
Atacand 16 mg tablet2.49USD tablet
Atacand 4 mg tablet2.44USD tablet
Atacand 8 mg tablet2.44USD tablet
Atacand 16 mg Tablet1.28USD tablet
Atacand 32 mg Tablet1.28USD tablet
Atacand 8 mg Tablet1.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5534534No1994-01-092014-01-09Us
US5705517No1994-04-182011-04-18Us
CA2083305No2003-12-092012-11-19Canada
CA2040955No1998-02-032011-04-22Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00204 mg/mLALOGPS
logP5.12ALOGPS
logP7.53ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)4.23ChemAxon
pKa (Strongest Basic)1.45ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area143.34 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity177.42 m3·mol-1ChemAxon
Polarizability63.94 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8717
Caco-2 permeable-0.6208
P-glycoprotein substrateSubstrate0.5186
P-glycoprotein inhibitor INon-inhibitor0.848
P-glycoprotein inhibitor IINon-inhibitor0.9115
Renal organic cation transporterNon-inhibitor0.8266
CYP450 2C9 substrateNon-substrate0.7397
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6504
CYP450 1A2 substrateInhibitor0.5594
CYP450 2C9 inhibitorInhibitor0.5195
CYP450 2D6 inhibitorNon-inhibitor0.889
CYP450 2C19 inhibitorInhibitor0.5151
CYP450 3A4 inhibitorInhibitor0.7392
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testAMES toxic0.556
CarcinogenicityNon-carcinogens0.7561
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.5515 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.794
hERG inhibition (predictor II)Non-inhibitor0.5837
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Cervenka L, Navar LG: Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S197-201. [PubMed:9892163]
  3. Malmqvist K, Kahan T, Dahl M: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000 May;13(5 Pt 1):504-11. [PubMed:10826401]
  4. Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K: Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res. 1996 Jun;19(2):75-81. [PubMed:10968199]
  5. Engelhorn T, Doerfler A, Heusch G, Schulz R: Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett. 2006 Oct 2;406(1-2):92-6. Epub 2006 Aug 9. [PubMed:16901636]
  6. Caballero-George C, Vanderheyden PM, Solis PN, Gupta MP, Pieters L, Vauquelin G, Vlietinck A: In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor. Eur J Pharmacol. 2003 Jan 5;458(3):257-62. [PubMed:12504781]
  7. McInnes GT, O'Kane KP, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo HF: Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000 Apr;14(4):263-9. [PubMed:10805052]
  8. Vauquelin G, Fierens F, Van Liefde I: Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl. 2006 Mar;24(1):S23-30. [PubMed:16601569]
  9. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275]
  10. Meredith PA: Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin. 2007 Jul;23(7):1693-705. [PubMed:17588300]
  11. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. McClellan KJ, Goa KL: Candesartan cilexetil. A review of its use in essential hypertension. Drugs. 1998 Nov;56(5):847-69. [PubMed:9829158]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]

Drug created on June 13, 2005 07:24 / Updated on November 22, 2017 12:31